Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Promising therapeutic targets in neuroblastoma.

Matthay KK, George RE, Yu AL.

Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939. Review.

2.

[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P.

Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Review. French.

PMID:
21609890
3.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP.

Oncogene. 2012 Nov 15;31(46):4859-67. doi: 10.1038/onc.2011.647. Epub 2012 Jan 23. Erratum in: Oncogene. 2012 Nov 15;31(46):4888. Vigny, M [added]; Mazot, P [added].

4.

131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.

DuBois SG, Matthay KK.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):53-65. Review.

PMID:
23474635
5.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
6.

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

DuBois SG, Matthay KK.

Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48. doi: 10.1016/j.nucmedbio.2008.05.002. Review.

7.

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group.

N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123.

8.

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A.

Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Review.

PMID:
24166094
9.

Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.

Reuland P, Geiger L, Thelen MH, Handgretinger R, Haase B, Müller-Schauenburg W, Niethammer D, Bares R.

J Pediatr Hematol Oncol. 2001 Oct;23(7):437-42.

PMID:
11878578
10.

Treatment of high-risk neuroblastoma with anti-GD2 antibodies.

Castel V, Segura V, Cañete A.

Clin Transl Oncol. 2010 Dec;12(12):788-93. doi: 10.1007/s12094-010-0600-y. Review.

PMID:
21156409
11.

A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.

Hoefnagel CA, Rutgers M, Buitenhuis CK, Smets LA, de Kraker J, Meli M, Carrel F, Amstutz H, Schubiger PA, Novak-Hofer I.

Eur J Nucl Med. 2001 Mar;28(3):359-68.

PMID:
11315605
12.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

13.

Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.

Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP.

Pediatr Blood Cancer. 2015 Jan;62(1):5-11. doi: 10.1002/pbc.25200. Epub 2014 Aug 30. Review.

14.

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN.

Mol Immunol. 2005 Jul;42(11):1311-9. Epub 2005 Apr 7.

PMID:
15950727
15.

Contemporary approach to diagnosis and treatment of neuroblastoma.

Charron M.

Q J Nucl Med Mol Imaging. 2013 Mar;57(1):40-52. Review.

PMID:
23474634
16.

Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM.

J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73.

PMID:
14528098
17.

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.

Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ.

J Clin Oncol. 2002 Apr 15;20(8):2142-9.

PMID:
11956276
18.

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.

Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S.

PLoS One. 2014 Feb 10;9(2):e87210. doi: 10.1371/journal.pone.0087210. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e103395.

19.

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K.

Pediatr Blood Cancer. 2013 May;60(5):879-84. doi: 10.1002/pbc.24351. Epub 2012 Sep 28.

PMID:
23024113
20.

Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma.

Taggart D, Dubois S, Matthay KK.

Q J Nucl Med Mol Imaging. 2008 Dec;52(4):403-18. Review.

Items per page

Supplemental Content

Write to the Help Desk